Key Takeaways
- •The global rollout of weight loss medications has entered a new chapter.
- •The decision to start with the UAE reflects a careful strategic assessment.
- •The Emirates Drug Establishment approved the Wegovy pill for weight management and for reducing the risk of cardiovascular events in high-risk patients earlier this week.
Novo Nordisk Launches Oral Wegovy in the UAE: First Market Beyond the U.S.
The global rollout of weight loss medications has entered a new chapter. Novo Nordisk, the Danish pharmaceutical company, announced on Wednesday that it is launching its oral Wegovy pill in the United Arab Emirates. This marks the first time the pill format of the popular GLP-1 drug semaglutide is being introduced outside of the United States.
The decision to start with the UAE reflects a careful strategic assessment. Emil Kongshøj Larsen, executive vice president of International Operations at Novo Nordisk, explained that the company’s approach will be guided by patient demand, the readiness of healthcare professionals, and the strength of healthcare and telehealth infrastructure in each market. “The UAE has demonstrated strong momentum across all of these areas, and we look forward to bringing Wegovy pill to additional select countries in the coming months,” he said.
The Emirates Drug Establishment approved the Wegovy pill for weight management and for reducing the risk of cardiovascular events in high-risk patients earlier this week. This regulatory green light sets the stage for a competitive global expansion in the GLP-1 drug space, which analysts project could exceed $100 billion in annual sales by 2030.
Why the Pill Format Matters
The oral formulation of semaglutide represents a significant convenience factor over the injectable versions, such as Ozempic and Wegovy injections. Many patients experience needle aversion or find daily injections burdensome. A pill offers a more familiar route of administration and may improve adherence.
Larsen told CNBC in May that the pill format has been appealing to many patients in the United States and that he expected this preference would be replicated worldwide. He also highlighted what he described as the Wegovy pill’s “superior efficacy” compared to competitor products. Clinical studies have suggested that the oral semaglutide formulation leads to more pronounced weight loss than Eli Lilly’s newly launched weight loss pill, Foundayo (orforglipron). However, no head to head clinical trial has yet directly compared the two drugs. Additionally, the Wegovy pill has been shown to confer certain cardiovascular benefits beyond weight reduction.
The mechanism of GLP-1 drugs involves mimicking a natural hormone called glucagon-like peptide 1. This hormone increases insulin secretion after meals, delays gastric emptying, and signals satiety to the brain. Oral semaglutide is coformulated with a permeation enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate) to allow absorption in the stomach. This bioavailability strategy is distinct from other oral GLP-1 drugs in development, including Lilly’s orforglipron, which is a small molecule, not a peptide.
Market Dynamics and Competition
While Novo Nordisk was the first company to bring GLP-1 drugs to market for obesity treatment, it has been losing ground to its chief rival Eli Lilly. In the second quarter of 2025, Lilly’s injectable drug Mounjaro (tirzepatide) overtook Novo’s Ozempic (injectable semaglutide) as the best selling GLP-1 drug globally. The weight loss wars have become intensely competitive as both companies expand their pipelines and dosage forms.
The United States remains the dominant market for both companies, accounting for more than half of their respective sales. The Wegovy pill was launched in the U.S. in early 2025, and by the first quarter of that year it accounted for 3% of Novo’s total sales, or 2.3 billion Danish kroner ($355 million). In early May 2025, Novo reported that total prescriptions of the pill had exceeded 2 million, and sales massively beat expectations despite the drug’s lower price point compared to injectables.
Lilly launched its own weight loss pill, Foundayo (orforglipron), in early April 2025. However, uptake has been slower. Lilly CEO David Ricks has acknowledged that Foundayo is a “totally new drug and brand” and that it will take time to establish it in the market.
Novo had previously announced in early May, alongside its first quarter earnings report, that pending approvals it would launch the pill in certain markets outside the U.S. in the second half of 2026, without naming specific countries at that time. The UAE is ahead of that schedule. Larsen told CNBC in May that Novo was “all in” on launching the Wegovy pill in overseas markets, calling it a “major opportunity.”
Investor Outlook and Challenges
The success of the Wegowy pill in the U.S. has led some investors to become cautiously optimistic that Novo can claw back some of the market share it lost to Lilly. However, the company’s stock has not reflected that optimism. Novo shares were down about 15% year to date as of the article’s publication. The decline is largely attributed to two factors: a gloomy financial guidance provided in early 2025, and a clinical trial result that showed its next generation weight loss drug, CagriSema (a combination of cagrilintide and semaglutide), failed to match the efficacy of Lilly’s Zepbound (tirzepatide).
Despite these headwinds, the global expansion of the Wegovy pill offers a new avenue for growth. Many countries outside the U.S. have high obesity rates and underpenetrated markets for anti obesity medications. The UAE, for example, has a rapidly developing healthcare system with strong infrastructure in telemedicine and a health conscious population that is increasingly seeking pharmacological interventions.
Scientific Context of Oral GLP-1s
The development of oral versions of GLP-1 receptor agonists has been a major focus for pharmaceutical companies. Semaglutide (the active ingredient in Wegovy and Ozempic) is a large peptide molecule that is poorly absorbed in the gastrointestinal tract. The SNAC technology used in the oral version works by increasing the local pH in the stomach and facilitating transcellular transport of the peptide. This innovation opened the door for a full class of oral GLP-1 drugs.
Lilly’s Foundayo is not a peptide but a small molecule GLP-1 receptor agonist, which may have different absorption characteristics and tolerability profiles. The lack of a direct comparative trial means that clinicians and patients must rely on indirect evidence from separate studies. The cardiovascular benefits of semaglutide are well documented from the SELECT trial and other outcomes studies, which showed a reduction in major adverse cardiovascular events in patients with overweight or obesity and established cardiovascular disease.
Regulatory and Infrastructure Considerations
Novo’s decision to launch in the UAE was not arbitrary. The company evaluated several criteria: patient demand, healthcare professional readiness, and telehealth infrastructure. The UAE has invested heavily in digital health platforms, and its regulatory agency, the Emirates Drug Establishment, has shown willingness to swiftly approve drugs for metabolic indications.
This structured approach suggests that the next countries to receive the Wegovy pill will likely be those with similar profiles: advanced healthcare systems, high obesity prevalence, and strong regulatory pathways. Markets in the Middle East, parts of Europe, and potentially Asia are candidates.
Frequently Asked Questions
Q: Why did Novo Nordisk choose the United Arab Emirates as the first market outside the U.S. for the Wegovy pill?
A: The UAE met several criteria set by Novo, including strong patient demand, readiness among healthcare professionals to prescribe and manage GLP-1 therapy, and a robust healthcare and telehealth infrastructure. The country’s regulator, the Emirates Drug Establishment, also approved the pill for weight management and cardiovascular risk reduction earlier this week, streamlining the launch.
Q: How does the Wegovy pill compare to Eli Lilly’s Foundayo pill?
A: Studies have suggested that the Wegovy pill (oral semaglutide) results in more pronounced weight loss than Foundayo and offers certain cardiovascular benefits. However, no clinical trial has directly compared the two drugs head to head. Foundayo is a small molecule GLP-1 agonist, whereas Wegovy pill is a peptide coformulated with an absorption enhancer.
Q: What percentage of Novo Nordisk’s total sales does the Wegovy pill represent?
A: In the first quarter after its U.S. launch, the Wegovy pill accounted for 3% of Novo’s total sales, equating to 2.3 billion Danish kroner ($355 million). Despite this modest share, total prescriptions exceeded 2 million in early May, and sales beat expectations.
Q: Why have Novo Nordisk’s shares declined despite the Wegovy pill’s success?
A: Novo shares were down about 15% year to date due to two main factors: a gloomy financial guidance issued in early 2025, and a clinical trial showing that its next generation weight loss drug CagriSema failed to match the efficacy of Lilly’s Zepbound. Investors remain cautious about the company’s long term competitive position.